Navigation Links
Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
Date:2/8/2012

ALISO VIEJO, Calif., Feb. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the results of the study entitled "Efficacy and Safety of Dextromethorphan/Quinidine (AVP-923) at Two Dosage Levels for Diabetic Neuropathic Pain: A Double-Blind, Placebo-Controlled, Multicenter Study" have been published in the February edition of the journal Pain Medicine.

"Throughout a 13-week trial, AVP-923 was effective, with an acceptable safety profile, for treatment of diabetic peripheral neuropathic pain. The findings indicate that other fixed-dose combinations of AVP-923 should be studied to improve overall tolerability while maintaining significant efficacy," said Aziz Shabaini, MD, Medical Director of the Nerve and Muscle Center, Texas.

AVP-923 is a combination of dextromethorphan (DM) and quinidine (Q). AVP-923 is currently being studied in a Phase II clinical trial (the PRIME study) in central neuropathic pain in patients with multiple sclerosis.

"Today's publication in a leading peer-review medical journal complements a body of scientific literature suggesting that dextromethorphan could be efficacious in neuropathic pain," said Joao Siffert, MD, senior vice president of research and development at Avanir. "These results provide additional rationale in support of the ongoing PRIME study, which is evaluating the combination of dextromethorphan and quinidine in central neuropathic pain in patients with multiple sclerosis."

Study Design

In a 13-week, phase III, randomized, controlled trial, 379 adults with daily symmetric diabetic peripheral neuropathy (DPN) leg pain for >3 months received double-blind placebo, DMQ 45/30 mg, or DMQ 30/30 mg, administered once daily for 7 days and twice daily thereafter. Efficacy measures included four pain rating scales applied daily using patient diaries, and anoth
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
2. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
3. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
4. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
5. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
6. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
7. Avanir Pharmaceuticals to Participate in Two Investor Conferences
8. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
9. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
10. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
11. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Calif. , May 23, 2013 Amgen (NASDAQ: ... 38 th Annual  Healthcare Conference on Thursday, May 30, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... at Amgen, will present at the conference. Live audio of ... Amgen,s website, www.amgen.com , under Investors. A replay of ...
(Date:5/23/2013)... HOUSTON , May 23, 2013  A recently ... in Houston, Texas , demonstrates that ... simultaneously increasing cancer detection. The study, ... An Observational Study," was led by Stephen ... June issue of the American Journal of Roentgenology ...
(Date:5/23/2013)... 2013 Anthem Blue Cross patients with HIV/AIDS ... them to obtain their medications by mail order under ... Kallas LLC.  The lawsuit, filed in ... Cross,s mandatory mail order program announced late last year ... "This settlement brings to a close a ...
Breaking Medicine Technology:First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
... , CAMBRIDGE, Mass., Dec. 3, 2009 ... (NYSE: RTN ), has licensed its patented, award-winning ... FUJIFILM intends to interface the SDM technology with the Aspire ... digital mammography system will deliver stereo images for 3-D viewing. ...
... , , MAPLE ... the next phase of its strategic plan for central nervous ... developed program for the management of epilepsy. USL255 is being ... phase III clinical trial in early 2010 for the adjunctive ...
Cached Medicine Technology:Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation 2Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation 3Upsher-Smith Announces Milestone in Development of CNS Strategy 2
(Date:5/26/2013)... "While the risk of infection following ... should be aware of the potential complications that can ... said Dr. Sadati. "It helps them to be more ... the blog, Dr. Sadati notes that less ... post-operative infection. However, patients who are undergoing any type ...
(Date:5/26/2013)... 26th May, 2013: While coupons can be ... use them. Be it due to a bad experience in ... only a few people who actually make use of coupons. ... spread awareness about coupons and allow people to use them ... there being various different opinions on why shoppers resist couponing, ...
(Date:5/26/2013)... Pain is an overall condition of sensory discomfort ... as acute pain and chronic. Pain has always been ... help. Every year about half a million people succumb ... used as primary pain relievers in which they decrease ... reducing the transmit of pain. Most common methods of ...
(Date:5/26/2013)... , , FRIDAY, May 24 (HealthDay News) -- We,ve all seen ... hurricane hits, the guy who decides to ride out the ... steer their cars alongside a scary-looking funnel cloud. Monday,s ... that Mother Nature isn,t something to gamble with -- that ... still get hurt and die. Yet, even now, when ...
(Date:5/26/2013)... May 26, 2013 According to a ... Medium Caliber & Small Caliber] (2012 – 2017)”, published ... reach $8.15 Billion by 2017 with a CACR of ... Data Tables , 87 Figures , ... “Ammunition Market” , http://www.marketsandmarkets.com/Market-Reports/ammunition-market-923.html , ...
Breaking Medicine News(10 mins):Health News:Orange County Surgeon Discusses the Risk of Infection after a Cosmetic Surgery 2Health News:Living on a Coupon Launched - Jessica Hacker Aims to Bring Professional Couponing Tips to the Masses 2Health News:Pain Management Drugs And Devices Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Pain Management Drugs And Devices Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Storm Chasers: Born to Be Wild? 2Health News:Storm Chasers: Born to Be Wild? 3Health News:Ammunition Market to Reach $8.15 Billion by 2017 at a CACR of 0.67% - New Report by MarketsandMarkets 2Health News:Ammunition Market to Reach $8.15 Billion by 2017 at a CACR of 0.67% - New Report by MarketsandMarkets 3Health News:Ammunition Market to Reach $8.15 Billion by 2017 at a CACR of 0.67% - New Report by MarketsandMarkets 4
... American Academy of Pediatrics (AAP) recommended all babies should ... deaths from Sudden Infant Death Syndrome have declined dramatically. ... and asphyxia, have increased. In an updated ... its guidelines on safe sleep for babies, with additional ...
... an association between shift work and increased risk of multiple ... age of 20 may be at risk for MS due ... Findings of this novel study appear today in Annals ... of the American Neurological Association and Child Neurology Society. ...
... the University of Sheffield is set to tackle the grand ... The FUTURAGE Road Map, created by Alan Walker, ... of Sociological Studies, will provide the European research agenda for ... was launched today at a meeting of the European Parliament ...
... more than half of cancer-free women will be among those ... about one in 12 will be referred for a biopsy. ... woman,s probability of having one of these false-positive episodes by ... over the course of a decade. A new ...
... October 17, 2011 (BRONX, NY) The Eunice ... Development, part of the National Institutes of Health, has ... Medicine of Yeshiva University $5.7 million to fund ... Disabilities Research Center (IDDRC). The grant supports Einstein,s ...
... , NEW YORK, October 17, 2011 -- Prof. ... (BGU), recently received the U.S. National Distinguished International Scientist ... Alcohol and Drug Abuse Resources (RADAR) Center. This ... National Institute on Drug Abuse (NIDA), which works with ...
Cached Medicine News:Health News:AAP expands guidelines for infant sleep safety and SIDS risk reduction 2Health News:AAP expands guidelines for infant sleep safety and SIDS risk reduction 3Health News:Shift work in teens linked to increased multiple sclerosis risk 2Health News:Project leads next decade of ageing research across Europe 2Health News:Project leads next decade of ageing research across Europe 3Health News:Project leads next decade of ageing research across Europe 4Health News:High rate of false-positives with annual mammogram 2Health News:High rate of false-positives with annual mammogram 3Health News:Einstein College of Medicine receives $5.7 million for developmental disabilities research 2Health News:BGU professor receives US National Distinguished International Science Award for substance abuse work 2
... SP Surgical Table combines innovation and design ... up to 1,000 lbs. You can safely ... normal and reverse orientation and have virtually ... patients.,The Amsco 3085 SP Table offers the ...
... 1st MPJ IMPLANT SYSTEM is a unique ... of the 1st metatarsal phalangeal joint resulting ... revision of a previous arthroplasty. The ... pain relief, superior function and longevity. ...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
... important part in our daily lives. But ... can cause severe handicaps. A decisive consideration ... was to produce a reconstructed joint function ... nearly possible.,The cementless RM Finger System has ...
Medicine Products: